z-logo
open-access-imgOpen Access
Amyloid precursor protein mutation E682K at the alternative β‐secretase cleavage β′‐site increases Aβ generation
Author(s) -
Zhou Lujia,
Brouwers Nathalie,
Benilova Iryna,
Vandersteen Annelies,
Mercken Marc,
Van Laere Koen,
Van Damme Philip,
Demedts David,
Van Leuven Fred,
Sleegers Kristel,
Broersen Kerensa,
Van Broeckhoven Christine,
Vandenberghe Rik,
De Strooper Bart
Publication year - 2011
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.1002/emmm.201100138
Subject(s) - genetics , library science , biology , computer science
BACE1 cleaves the amyloid precursor protein (APP) at the β‐cleavage site (Met 671 –Asp 672 ) to initiate the generation of amyloid peptide Aβ. BACE1 is also known to cleave APP at a much less well‐characterized β′‐cleavage site (Tyr 681 –Glu 682 ). We describe here the identification of a novel APP mutation E682K located at this β′‐site in an early onset Alzheimer's disease (AD) case. Functional analysis revealed that this E682K mutation blocked the β′‐site and shifted cleavage of APP to the β‐site, causing increased Aβ production. This work demonstrates the functional importance of APP processing at the β′‐site and shows how disruption of the balance between β‐ and β′‐site cleavage may enhance the amyloidogenic processing and consequentially risk for AD. Increasing exon‐ and exome‐based sequencing efforts will identify many more putative pathogenic mutations without conclusive segregation‐based evidence in a single family. Our study shows how functional analysis of such mutations allows to determine the potential pathogenic nature of these mutations. We propose to classify the E682K mutation as probable pathogenic awaiting further independent confirmation of its association with AD in other patients. →See accompanying Closeup by John Hardy and Rita Guerreiro DOI 10.1002/emmm.201100139

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here